Related Experiment Video
Updated: Aug 13, 2026

Application of an Amplitude-integrated EEG Monitor (Cerebral Function Monitor) to Neonates
Published on: September 6, 2017
Prevention of apnea and bradycardia in low-birthweight infants
Insights
Theophylline effectively prevents severe apnea in low-birthweight infants. This treatment controlled prolonged apneic spells and reduced shorter ones, with no observed toxicity at therapeutic serum levels.
Area of Science:
- Neonatal Medicine
- Pediatric Pharmacology
Background:
- Apnea is a significant concern in low-birthweight infants.
- Accurate detection and quantification of apnea are crucial for effective treatment.
Purpose of the Study:
- To evaluate the efficacy of theophylline in preventing severe apnea in low-birthweight infants.
- To correlate serum theophylline levels with apnea control.
Main Methods:
- Seventeen low-birthweight infants received oral theophylline every six hours.
- Apnea was monitored using 13-hour pneumogram recordings.
- Serum theophylline levels were measured and correlated with apneic episodes.
Main Results:
- Theophylline (1.5-4.0 mg/kg) achieved serum concentrations of 6.6-11.0 mug/ml.
- Apneic spells exceeding 20 seconds were completely controlled.
- Shorter apneic episodes (10-19 seconds) and associated bradycardia were significantly reduced.
- No toxicity was observed at these therapeutic serum levels.
Conclusions:
- Theophylline is effective in managing apnea of prematurity.
- Individualized dosing based on apnea quantitation and serum levels is recommended.
- Theophylline offers a safe and effective therapeutic option for apneic infants.
Abstract:
The efficacy of theophylline in preventing severe apnea was evaluated in 17 low-birthweight infants (mean weight, 1,400 gm). Apnea was detected and accurately quantified by 13-hour pneumogram recordings and correlated with serum theophylline levels. Nursing observations coupled with on-line alarm systems detected only 39% of severe apneic episodes as compared to the pneumogram recording technique. Theophylline in six hourly oral doses(1.5 to 4.0 mg/kg) yielded two-hour serum concentrations of 6.6 to 11.0 mug/ml which completely controlled apneic spells exceeding 20 seconds in duration and markedly reduced 10- 19-second apneic episodes and any resultant bradycardia. At these serum levels, toxicity was not observed. Therapy with theophylline should be instituted at a dose of 2 to 3 mg/kg every six hours and the optimum therapeutic dose should be individualized as determined by objective quantitation of apnea and serum theophylline concentration.
Related Concept Videos
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
Fetal Circulation
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Cardiopulmonary Resuscitation I: Adult
Cardiopulmonary Resuscitation II: ACLS Airway Management
Cardiopulmonary Resuscitation IV: Pharmacological Management

